Finasteride vs Spironolactone: Head-to-Head Efficacy for Skin, Hair, and Hormonal Acne

How the two drugs work

Finasteride and spironolactone both reduce androgen signaling, but at different steps.

Finasteride inhibits 5-alpha reductase type II, the enzyme that converts testosterone into dihydrotestosterone (DHT). This is a selective step: finasteride lowers DHT substantially without materially changing total testosterone. That selectivity is why it targets androgenetic alopecia, a condition in which DHT-driven miniaturization of the hair follicle is the dominant mechanism. Finasteride does not block testosterone or other androgens from acting on the androgen receptor itself.

Spironolactone works differently. It competes with androgens (testosterone, DHT, and others) at the androgen receptor, so it blunts the effect of whichever androgen is present rather than targeting one enzymatic step. It also has weak inhibitory effects on androgen synthesis and, separately, its original and still-approved pharmacology as a mineralocorticoid (aldosterone) receptor antagonist, which is why it is used as a potassium-sparing diuretic in heart failure and edema.

This mechanistic difference explains the clinical split described below: finasteride's narrow, DHT-specific action fits male-pattern hair loss well; spironolactone's broader receptor blockade fits hormonal acne, where several androgens contribute to sebum production, and it is also used off-label for female-pattern hair loss.

Direct comparison table

Efficacy for hair loss

Male androgenetic alopecia is where finasteride has the deepest evidence base. A widely cited randomized controlled trial (Kaufman et al., with a five-year extension) reported sustained increases in hair count on the vertex scalp in men taking finasteride 1 mg compared with placebo, with the treated group gaining hair count on a standardized measurement area while the placebo group lost hair over the same period. The exact hair-count figures commonly cited from this trial should be verified against the original publication before being quoted to a patient, since we could not confirm the precise numbers against a verified primary source for this draft.

Spironolactone is not FDA-approved for any form of hair loss. Its use in female-pattern hair loss is off-label and rests mainly on retrospective and observational cohorts rather than placebo-controlled trials. Reported rates of stabilization or improvement in these cohorts are meaningful but should be read as observational evidence, not trial-level proof, and specific percentage figures require verification against the primary literature before being used in patient counseling.

The practical divide is sharp: finasteride dominates in male androgenetic alopecia, where DHT is the primary driver and the trial evidence is strongest. Spironolactone fills a gap for women, where finasteride is rarely used because of teratogenic risk and because female-pattern hair loss may involve androgen receptor sensitivity that a DHT-selective drug does not fully address. In routine practice the two drugs almost never compete for the same patient.

Efficacy for hormonal acne

Spironolactone has the stronger evidence profile for acne. Studies in adult women with hormonal acne, including a hybrid systematic review of oral spironolactone for acne vulgaris in adult females, have reported reductions in inflammatory lesion counts at doses in the 50-200 mg/day range, with response rates that vary widely across studies depending on dose and study design. Evidence quality has generally been described as moderate rather than high, reflecting a mix of small trials and observational series rather than a single large definitive trial.

Finasteride has essentially no acne-specific evidence. A small number of case reports have described finasteride at the 5 mg (BPH) dose in women with severe hirsutism and acne, but sample sizes are too small to draw efficacy conclusions, and finasteride has not been tested head-to-head against spironolactone or against placebo specifically for acne in an adequately powered trial.

If the primary complaint is hormonal acne, the available evidence favors spironolactone. Finasteride has no established role in acne management.

Dosing and how long it takes to know if it's working

Finasteride for hair loss is dosed at 1 mg daily. Visible improvement typically takes three to six months, and the drug generally must be continued indefinitely to maintain results; stopping is followed by a return of hair loss over roughly six to twelve months as DHT levels normalize. The 5 mg tablet (marketed for BPH) is sometimes split off-label for cost reasons, a practice the FDA has not evaluated or endorsed for hair loss dosing.

Spironolactone for dermatologic use typically starts at 25-50 mg daily, titrating to 100-200 mg based on response and tolerability. Acne improvement usually becomes apparent around three months, with peak effect closer to six to nine months. As with finasteride, acne often recurs after stopping the drug, and many women remain on long-term maintenance at the lowest effective dose.

Neither drug produces fast results. A reasonable clinical rule is to avoid declaring either drug a failure before three months of consistent use.

Side effects: where the risks genuinely differ

The two side-effect profiles barely overlap, which is one of the more useful facts for patient counseling.

Finasteride's principal concerns are sexual: decreased libido, erectile dysfunction, and reduced ejaculate volume have been reported in a minority of men in controlled trials. A contested entity sometimes called "post-finasteride syndrome" describes persistent sexual, neurological, and psychological symptoms that some men report after stopping the drug. The FDA added label language addressing post-marketing reports of these persistent symptoms; the underlying mechanism and true prevalence remain debated in the literature, and this should be described to patients as an area of genuine scientific disagreement rather than a settled question.

Spironolactone's risks track its mineralocorticoid activity. The most clinically significant concern is hyperkalemia, particularly in patients with renal impairment or those taking ACE inhibitors, ARBs, or potassium supplements. Breast tenderness and menstrual irregularity are commonly reported at dermatologic doses, more so at higher doses. An often-cited retrospective analysis in healthy young women taking spironolactone for acne found routine potassium monitoring detected essentially no clinically significant hyperkalemia in that low-risk population, a finding that has influenced some dermatology practices to limit monitoring in healthy patients under 45 with normal baseline renal function. Patients with kidney disease, heart failure, or who take potassium-affecting medications still need regular monitoring.

Both drugs carry pregnancy contraindications tied to antiandrogen effects on a male fetus; current FDA labeling should be checked directly rather than relied on from this summary, since labeling language can change. Reliable contraception is essential for any premenopausal woman taking either drug.

Who actually gets which drug

Sex is the single biggest determinant in practice, and this is not arbitrary:

• Indication match. Men seeking antiandrogen therapy usually want hair preservation, where finasteride has the strongest trial support. Women seeking antiandrogen therapy usually want acne control or hair stabilization, both of which spironolactone addresses.
• Tolerability. Spironolactone can cause gynecomastia and breast tenderness in men, limiting its use for chronic dermatologic dosing in that population. Finasteride's sexual side effects are more relevant in men and do not cause feminizing effects.
• Teratogenicity and prescribing comfort. Finasteride's teratogenic risk creates a strong barrier to prescribing it to women of reproductive age, even though a small body of evidence has explored finasteride 2.5-5 mg daily for female androgenetic alopecia in postmenopausal women specifically (a population without pregnancy risk). Spironolactone is also teratogenic, but decades of use in young women for acne and PCOS have normalized a workflow of drug-plus-reliable-contraception.

The genuine overlap zone is narrow: postmenopausal women with androgenetic alopecia who cannot tolerate minoxidil. Here both off-label finasteride (roughly 1-5 mg) and spironolactone (100-200 mg) are reasonable considerations, and the choice often comes down to comorbidities, particularly whether the patient's renal function, blood pressure, and baseline potassium make spironolactone's diuretic and potassium-raising effects a good or bad fit.

Monitoring in practice

Finasteride requires minimal monitoring in healthy men. A baseline PSA is recommended in men over 40 because finasteride roughly halves PSA values, which can complicate prostate cancer screening if the baseline isn't documented before starting. Beyond that, routine blood work is not standard for a healthy man on 1 mg daily.

Spironolactone monitoring has traditionally included periodic potassium and renal function checks, though practice is shifting toward baseline-only monitoring in healthy women under 45 with normal renal function, based on the low observed rate of significant hyperkalemia in that group in retrospective data. Patients with kidney disease, heart failure, or concurrent potassium-sparing medications should continue regular monitoring. Blood pressure checks at initiation are reasonable, since clinically significant hypotension can occur, though it is uncommon at dermatologic doses.

Can the two be combined?

Combination use is rare and poorly studied for skin and hair indications. Case series have described finasteride plus spironolactone in transgender women undergoing feminizing hormone therapy, where the goal is maximal androgen suppression rather than treating acne or hair loss specifically. There is no published evidence supporting combined finasteride-plus-spironolactone therapy for acne or androgenetic alopecia in cisgender patients.

The theoretical logic is coherent: finasteride reduces DHT production upstream while spironolactone blocks the receptor downstream. In practice, the sex-specific prescribing patterns above mean the combination almost never comes up. A man with androgenetic alopecia would not typically also receive spironolactone, and a woman with hormonal acne would not typically also receive finasteride. If a clinician is considering dual therapy in an unusual case, additive effects on potassium (spironolactone) and sexual function (both drugs) require careful discussion, and no dermatology guideline endorses this combination for skin or hair indications.

Cost and access

Both finasteride and spironolactone are available as low-cost generics, and both are commonly prescribed through telehealth. Because spironolactone carries FDA-approved indications for heart failure, edema, and hyperaldosteronism, insurance coverage for the drug itself is often more straightforward than for finasteride, where insurers frequently classify hair loss treatment as cosmetic and deny coverage regardless of medical rationale. Dermatologic use of spironolactone may still require prior authorization for the off-label indication at some plans. Specific cash prices change over time and vary by pharmacy and region; check a current pricing tool rather than relying on a fixed number, since cost quotes go stale quickly.

What is established, what is plausible, and what is not established

Established: Finasteride reduces DHT and has trial-level evidence for slowing or reversing hair loss in men with androgenetic alopecia. Spironolactone blocks the androgen receptor and has supporting clinical evidence, of moderate overall quality, for reducing inflammatory acne lesions in adult women. The two drugs have essentially non-overlapping side-effect profiles tied to their different mechanisms.

Plausible but not proven at trial level: Spironolactone's benefit for female-pattern hair loss, which rests mainly on retrospective and observational data rather than placebo-controlled trials. Finasteride's use in postmenopausal women for hair loss, based on a small evidence base rather than large trials.

Not established: A head-to-head comparison of the two drugs for any single endpoint. Combination therapy for dermatologic indications. Finasteride's efficacy for acne of any kind.

If a specific numeric efficacy figure (percentage improvement, exact hair count, precise response rate) matters for a clinical decision, verify it against the primary trial or systematic review directly rather than relying on a secondary summary, including this one.